AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Treatment of Ischemic Stroke to Prevent Neurodegeneration

Technology Benefits: - Simulated human tests after stroke: grasping, holding, voluntary hand touching and leaning- Results in almost complete functional recovery - Treatment can be administered up to 26 hours after an event- Uses FDA Drugs: Fluoxetine (Prozac, Sarafem), Simvastatin (Zocor) - A follow on treatment, which ~90% of ischemic stroke patients do not receive- Safer than thrombolytic therapy, which produces negative side effects 1 in 15 patients, some cases being fatal

Technology Application: - Treatment of ischemic stroke

Detailed Technology Description: None

Supplementary Information: Inventor: Okun, Michael S. | Foote, Kelly D.
Priority Number: US8295935B2
IPC Current: A61N000118
US Class: 607045
Assignee Applicant: University of Florida Research Foundation Inc.inesville
Title: Multiple lead method for deep brain stimulation
Usefulness: Multiple lead method for deep brain stimulation
Summary: For treatment of movement-related disorder e.g. ataxia, blepharospasm, chorea, dysphonia, dystonic disorder, gait disorder, multiple sclerosis, myoclonus, spasticity, tardive dyskinesia, tics, Parkinson's disease, Huntington's disease.
Novelty: Deep brain stimulation (DBS) method for treatment of movement-related disorder, involves applying electrical stimulation to at least one of electrical leads under conditions to eliminate or ameliorate symptom of movement-related disorder

Industry: Disease Diagnostic/Treatment

Sub Category: Other Disease

*Abstract: The inventor has developed a novel approach to the treatment of ischemic stroke, lack of blood to the brain, and traumatic brain injury, which may lead to neurodegeneration. The method is superior to many others as it employs the use of existing FDA approved pharmaceuticals and may be administered up to 26 hours after the ΓÇ£eventΓÇØ. Laboratory results have been able to replicate recovery rates as high as 85-90% of original motor control based upon the Montoya Staircase. Rat data is available.

*Principal Investigator: Name: Adrian M. Corbett
Department:

Country/Region: USA

For more information, please click Here